Full Press Release Details
SAN DIEGO , Dec. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a biotechnology company focused on neurological and endocrine related disorders, announced today that Timothy P. Coughlin will be stepping down from his position as Chief Financial Officer in mid-February for personal reasons. The Board has initiated a replacement search and Mr. Coughlin has agreed to continue with the Company through 2017 to facilitate a smooth transition of responsibilities.
"On behalf of the board, shareholders and our employees, I want to thank Tim for his over ten years of tireless service as CFO of Neurocrine," said Dr. Kevin C. Gorman , President and Chief Executive Officer of Neurocrine. "Tim has been a tremendous person to work with and a key part of the team, which orchestrated the turnaround of Neurocrine. I am very pleased that we will continue to work together through a transition period. Through his leadership we are in a strong financial position that allows us to continue to execute on our commercialization and clinical plans."
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two programs are elagolix, a gonadotropin-releasing hormone antagonist in Phase III development for women's health that is partnered with AbbVie Inc., and INGREZZA, a vesicular monoamine transporter 2 inhibitor for which an NDA has been filed with the FDA for the treatment of tardive dyskinesia, and is in Phase II development for patients with Tourette syndrome. Neurocrine plans to commercialize INGREZZA in the United States upon approval of the NDA by the FDA.
Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com .
SOURCE Neurocrine Biosciences, Inc.